Webcast:
Navigating New Waters for Advanced or Recurrent Endometrial Cancer
Statement of Need
Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifies clinically significant molecular subtypes. This information assists clinicians in creating treatment plans tailored to specific tumor phenotypes and individual needs, including those patients with advanced and recurrent EC. Despite ringing endorsements and clear clinical applications, however, molecular profiling remains underutilized due to logistical challenges and a lack of clinician confidence. It is imperative that clinicians, in collaboration with the multidisciplinary team (MDT), become knowledgeable about this exciting technique and utilize it to enhance treatment decisions for patients.
In this CE Concepts live webcast, expert faculty will guide learners through integration of appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process. Faculty will also assess the latest efficacy and safety data for the treatment of EC with learners and develop guideline-concordant and patient-specific therapeutic plans for patients with newly diagnosed advanced or recurrent EC that incorporate MDT collaboration strategies.
Date: Wednesday, July 17, 2024 at 6:30 PM EST | United States
By entering your mobile phone number you agree that CE Concepts can send you periodic text messages about CME/CE activities. This free service is FCC CAN-SPAM compliant. You may update message preferences or unsubscribe at any time. Check your wireless provider for any message and data rates that may apply.
Expert Faculty
Richard T. Penson, MD, MRCP
Paula J. Anastasia, MN, RN, AOCN
Department of Pathology, Massachusetts General Hospital
Assistant Professor, Harvard Medical School
Boston, MA
Learning Objectives
At the conclusion of this activity, learners will be able to better:
- Integrate appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process
- Assess the latest efficacy and safety data for the treatment of EC factoring in updates to guidelines
- Develop a guideline-concordant and patient-specific therapeutic plan for patients with newly diagnosed advanced or recurrent EC utilizing MDT collaboration strategies
Financial Support
Supported by an educational grant from AstraZeneca Pharmaceuticals and Merck & Co., Inc., Rahway, NJ, USA.
Target Audience
Gynecologic oncologists, pathologists, gynecologists, physician associates (PAs), nurse practitioners (NPs), nurses, and other HCPs part of the MDT.
Credit Information
Jointly Accredited Provider
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Physicians (ACCME)
Creative Educational Concepts, LLC, designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
Note to Nurse Practitioners:
The content of this CNE activity pertains to Pharmacology.
American Nurses Credentialing Center with ILNA
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®Oncology Nursing Practice (Scientific Basis/Profession)
Symptom Management & Palliative Care
Psychosocial Dimensions of Care
AOCNP®/AOCNS®
Cancer Treatment
Side Effect & Symptom Management
Professional Practice
CPHON®
Cancer Treatment
Side Effect & Symptom Management
BMTCN®
Professional Performance
CBCN®
Diagnosis & Staging
Nursing Practice (Symptom Management, EoL Care, Professional)
PAs (AAPA)
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 09/17/2024. PAs should only claim credit commensurate with the extent of their participation.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Royal College MOC
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
For more information please visit: https://www.ceconcepts.com/activity/navigating-new-waters-for-advanced-or-recurrent-endometrial-cancer/